Richard G. Moore, M.D. | UR Medicine

Dr. Richard G. Moore

Claim this profile

University of Rochester

Studies Endometrial Adenocarcinoma
Studies Uterine Cancer
13 reported clinical trials
28 drugs studied

Area of expertise

1

Endometrial Adenocarcinoma

Richard G. Moore has run 6 trials for Endometrial Adenocarcinoma. Some of their research focus areas include:

Stage IV
Stage I
Stage III
2

Uterine Cancer

Richard G. Moore has run 5 trials for Uterine Cancer. Some of their research focus areas include:

Stage I
Stage III
Stage IV

Affiliated Hospitals

Image of trial facility.

University Of Rochester

Image of trial facility.

Highland Hospital

Clinical Trials Richard G. Moore is currently running

Image of trial facility.

CA 125 Blood Test

for Early Detection of Ovarian Cancer

The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are substances in the blood that may be related to ovarian cancer.

Recruiting

1 award

N/A

7 criteria

Image of trial facility.

Nivolumab +/− Ipilimumab

for Endometrial Cancer

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.

Recruiting

1 award

Phase 2

22 criteria

More about Richard G. Moore

Clinical Trial Related

3 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Richard G. Moore has experience with

  • Carboplatin
  • External Beam Radiation Therapy
  • Pembrolizumab
  • Cisplatin
  • Laboratory Biomarker Analysis
  • Paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Richard G. Moore specialize in?

Is Richard G. Moore currently recruiting for clinical trials?

Are there any treatments that Richard G. Moore has studied deeply?

What is the best way to schedule an appointment with Richard G. Moore?

What is the office address of Richard G. Moore?

Is there any support for travel costs?